Enoximone
Enoximone structure
|
Common Name | Enoximone | ||
|---|---|---|---|---|
| CAS Number | 77671-31-9 | Molecular Weight | 248.301 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H12N2O2S | Melting Point | 255-258°C | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Recovery of heart function in children with acute severe heart failure.
Transplantation 85(7) , 975-9, (2008) The prognosis of acute heart failure is such that many children are considered for transplantation. Recovery of severe heart failure in a proportion of patients diagnosed with either dilated cardiomyopathy or myocarditis is well recognized, and this complicat... |
|
|
Effects of enoximone on peripheral and central chemoreflex responses in humans.
Am. J. Physiol. Heart Circ. Physiol. 294(1) , H322-9, (2008) cAMP plays an important role in peripheral chemoreflex function in animals. We tested the hypothesis that the phosphodiesterase inhibitor and inotropic medication enoximone increases peripheral chemoreflex function in humans. In a single-blind, randomized, pl... |
|
|
[Tolerance of enoximone in patients with heart failure].
Z. Kardiol. 80 Suppl 4 , 93-7, (1991) Enoximone, a new phosphodiesterase-inhibitor with positive inotropic and vasodilating activities is available for intravenous use in patients with severe heart failure. A review of the current knowledge regarding the adverse effects of this substance reveals ... |
|
|
[Pharmacology and pharmacokinetics of enoximone].
Z. Kardiol. 80 Suppl 4 , 21-6, (1991) Enoximone belongs to the imidazole class of compounds, that possess positive inotropic and vasodilatory activities. These pharmacologic effects are caused by selective inhibition of a cAMP-specific phosphodiesterase in the heart and in the smooth muscle of bl... |
|
|
[Clinico-pharmacologic aspects of therapy with enoximone].
Z. Kardiol. 83 Suppl 2 , 7-14, (1994) Enoximone is an imidazole derivative which proved to be a selective inhibitor of the isoenzymes III/IV of the cAMP-specific phosphodiesterase. It has been shown in various experimental models that the drug exerts both positive inotropic and vasodilating prope... |
|
|
Use of oral enoximone in pharmacologic bridging to cardiac transplantation.
Z. Kardiol. 83 Suppl 2 , 15-9, (1994)
|
|
|
Enoximone, a post-operative inodilator in patients following mitral valve operation: a prospective and controlled study.
Eur. Heart J. 13(5) , 679-86, (1992) Inotropic support is often required for post-operative management of patients following mitral valve operation. The use of positive inotropes is limited by tolerance development and increase in myocardial oxygen demand. We have compared i.v. enoximone (E) (gr... |
|
|
Pharmacology and pharmacokinetics of enoximone.
Cardiology 77 Suppl 3 , 2-13; discussion 27-33, (1990) Enoximone is an inotropic vasodilating agent. Its principal effects are positive inotropism and vasodilation, which are not accompanied by changes in myocardial oxygen consumption. An inotropic dose of enoximone increases the level of cyclic AMP in the isolat... |
|
|
[Role of the enoximone-dobutamine combination in the treatment of congestive cardiac insufficiency].
Arch. Mal. Coeur Vaiss. 83 Spec No 3 , 33-7, (1990) Theoretically, there are two reasons for using the association of dobutamine and enoximone in patients with acute cardiac failure; the powerful vasodilator effect of enoximone and the different biochemical actions of the two drugs on the myocardial fibre affe... |
|
|
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Am. Heart J. 154(5) , 861-9, (2007) We determined whether low-dose oral enoximone could wean patients with ultra-advanced heart failure (UA-HF) from intravenous (i.v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective an... |